Many of the proteins that share genetic underpinnings with CHD are known drug targets (DrugBank database)18, or are currently under development as such (e.g., ANGPTL3, LPA, sICAM1, and GMP140). This evidence concerns the gene ANGPTL3 and coronary artery disorder.